These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 10385311)

  • 1. In silico predictions; in vivo veritas.
    De Groot AS; Rothman FG
    Nat Biotechnol; 1999 Jun; 17(6):533-4. PubMed ID: 10385311
    [No Abstract]   [Full Text] [Related]  

  • 2. Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice.
    Fifis T; Mottram P; Bogdanoska V; Hanley J; Plebanski M
    Vaccine; 2004 Nov; 23(2):258-66. PubMed ID: 15531045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic vaccines. Peptides of fortune.
    Janeway C
    Nature; 1991 Oct; 353(6347):792. PubMed ID: 1944552
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of APC in the selection of immunodominant T cell epitopes.
    Ma C; Whiteley PE; Cameron PM; Freed DC; Pressey A; Chen SL; Garni-Wagner B; Fang C; Zaller DM; Wicker LS; Blum JS
    J Immunol; 1999 Dec; 163(12):6413-23. PubMed ID: 10586031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
    Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct mapping of MHC class II epitopes.
    Milosevic S; Behrends U; Christoph H; Mautner J
    J Immunol Methods; 2005 Nov; 306(1-2):28-39. PubMed ID: 16168435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.
    Zeng G
    J Immunother; 2001; 24(3):195-204. PubMed ID: 11394496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative structure-activity relationship of peptides binding to the class II major histocompatibility complex molecule Aq associated with autoimmune arthritis.
    Holm L; Frech K; Dzhambazov B; Holmdahl R; Kihlberg J; Linusson A
    J Med Chem; 2007 May; 50(9):2049-59. PubMed ID: 17425295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based prediction of MHC-peptide association: algorithm comparison and application to cancer vaccine design.
    Schiewe AJ; Haworth IS
    J Mol Graph Model; 2007 Oct; 26(3):667-75. PubMed ID: 17493854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes.
    Felix NJ; Donermeyer DL; Horvath S; Walters JJ; Gross ML; Suri A; Allen PM
    Nat Immunol; 2007 Apr; 8(4):388-97. PubMed ID: 17322886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformation of MHC class II I-A(g7) is sensitive to the P9 anchor amino acid in bound peptide.
    Gardiner A; Richards KA; Sant AJ; Arneson LS
    Int Immunol; 2007 Sep; 19(9):1103-13. PubMed ID: 17855434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting peptides bound to I-Ag7 class II histocompatibility molecules using a novel expectation-maximization alignment algorithm.
    Chang KY; Suri A; Unanue ER
    Proteomics; 2007 Feb; 7(3):367-77. PubMed ID: 17211830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiplex mapping of CD4 T cell epitopes using class II tetramers.
    Yang J; James EA; Huston L; Danke NA; Liu AW; Kwok WW
    Clin Immunol; 2006 Jul; 120(1):21-32. PubMed ID: 16677863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes.
    Houghton CS; Engelhorn ME; Liu C; Song D; Gregor P; Livingston PO; Orlandi F; Wolchok JD; McCracken J; Houghton AN; Guevara-Patiño JA
    Vaccine; 2007 Jul; 25(29):5330-42. PubMed ID: 17570567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
    van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
    Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells.
    Lunde E; Munthe LA; Vabø A; Sandlie I; Bogen B
    Nat Biotechnol; 1999 Jul; 17(7):670-5. PubMed ID: 10404160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo MHC class II presentation of cytosolic proteins revealed by rapid automated tandem mass spectrometry and functional analyses.
    Dongre AR; Kovats S; deRoos P; McCormack AL; Nakagawa T; Paharkova-Vatchkova V; Eng J; Caldwell H; Yates JR; Rudensky AY
    Eur J Immunol; 2001 May; 31(5):1485-94. PubMed ID: 11465105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mhc-guided processing: binding of large antigen fragments.
    Sercarz EE; Maverakis E
    Nat Rev Immunol; 2003 Aug; 3(8):621-9. PubMed ID: 12974477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the minimal glycopeptide core recognized by T cells in a model for rheumatoid arthritis.
    Holm L; Kjellén P; Holmdahl R; Kihlberg J
    Bioorg Med Chem; 2005 Jan; 13(2):473-82. PubMed ID: 15598569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.